71
Participants
Start Date
June 11, 2020
Primary Completion Date
April 13, 2022
Study Completion Date
August 31, 2026
LY3295668 Erbumine
Administered orally.
Topotecan
Administered IV.
Cyclophosphamide
Administered IV.
Perth Children's Hospital, Perth
Hospital Universitari Vall d'Hebron, Barcelona
UZ Gent, Ghent
Children's Hospital of Philadelphia, Philadelphia
Istituto Nazionale dei Tumori, Milan
Hospital Infantil Universitario Niño Jesús, Madrid
Cincinnati Childrens Hospital Medical Center, Cincinnati
Universitätsklinikum Köln, Cologne
University of Chicago - Comer Children's Hospital, Chicago
Institut Curie, Paris
Texas Childrens Hospital, Houston
Children's Hospital Colorado, Aurora
UCSF Medical Center at Mission Bay, San Francisco
Dana-Farber Cancer Institute, Boston
Centre Leon Berard, Lyon
National Cancer Center Hospital, Chuo-ku
Alder Hey Children's Hospital, Liverpool
New Approaches to Neuroblastoma Therapy Consortium (NANT)
UNKNOWN
Innovative Therapies for Children with Cancer in Europe (ITCC)
UNKNOWN
Eli Lilly and Company
INDUSTRY